Alzheimer's disease and the blood-brain barrier: Past, present and future

Gene Bowman, Joseph Quinn

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Successful prevention and treatment of late-onset Alzheimer's disease (AD) is a high priority for industrialized societies where the incidence is growing rapidly. Much of the underlying biology leading to AD is unknown, and the more knowledge we gain the more we appreciate the complexities involved. Popular etiologic hypotheses have largely ignored the blood-brain barrier (BBB) as an important factor contributing to the pathologic hallmarks of this most common form of dementia. Evidence idenfying BBB dysfunction in AD or patients at risk (i.e. those with mild cognitive impairment) continue to escalate. This review highlights methodological issues facing investigators assessing BBB integrity in living patients while also discussing whether the BBB dysfunction is a cause, effect or epiphenomenon in AD. Rationale for future research pursuits aimed at describing the role of BBB function in AD pathogenesis is also presented.

Original languageEnglish (US)
Pages (from-to)47-57
Number of pages11
JournalAging Health
Volume4
Issue number1
DOIs
StatePublished - Feb 2008

Fingerprint

Blood-Brain Barrier
Alzheimer Disease
Dementia
Research Personnel
Incidence
Therapeutics

Keywords

  • Albumin
  • Alzheimer's disease
  • Amyloid
  • Blood-brain barrier
  • Cerebral amyloid angiopathy
  • Cholesterol
  • Computed tomography
  • Homocysteine
  • Imaging
  • LRP-1
  • MRI
  • PET
  • RAGE

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Medicine(all)

Cite this

Alzheimer's disease and the blood-brain barrier : Past, present and future. / Bowman, Gene; Quinn, Joseph.

In: Aging Health, Vol. 4, No. 1, 02.2008, p. 47-57.

Research output: Contribution to journalArticle

@article{4d4c4ca9890a47c9ae804485f56a5465,
title = "Alzheimer's disease and the blood-brain barrier: Past, present and future",
abstract = "Successful prevention and treatment of late-onset Alzheimer's disease (AD) is a high priority for industrialized societies where the incidence is growing rapidly. Much of the underlying biology leading to AD is unknown, and the more knowledge we gain the more we appreciate the complexities involved. Popular etiologic hypotheses have largely ignored the blood-brain barrier (BBB) as an important factor contributing to the pathologic hallmarks of this most common form of dementia. Evidence idenfying BBB dysfunction in AD or patients at risk (i.e. those with mild cognitive impairment) continue to escalate. This review highlights methodological issues facing investigators assessing BBB integrity in living patients while also discussing whether the BBB dysfunction is a cause, effect or epiphenomenon in AD. Rationale for future research pursuits aimed at describing the role of BBB function in AD pathogenesis is also presented.",
keywords = "Albumin, Alzheimer's disease, Amyloid, Blood-brain barrier, Cerebral amyloid angiopathy, Cholesterol, Computed tomography, Homocysteine, Imaging, LRP-1, MRI, PET, RAGE",
author = "Gene Bowman and Joseph Quinn",
year = "2008",
month = "2",
doi = "10.2217/1745509X.4.1.47",
language = "English (US)",
volume = "4",
pages = "47--57",
journal = "Aging Health",
issn = "1745-509X",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Alzheimer's disease and the blood-brain barrier

T2 - Past, present and future

AU - Bowman, Gene

AU - Quinn, Joseph

PY - 2008/2

Y1 - 2008/2

N2 - Successful prevention and treatment of late-onset Alzheimer's disease (AD) is a high priority for industrialized societies where the incidence is growing rapidly. Much of the underlying biology leading to AD is unknown, and the more knowledge we gain the more we appreciate the complexities involved. Popular etiologic hypotheses have largely ignored the blood-brain barrier (BBB) as an important factor contributing to the pathologic hallmarks of this most common form of dementia. Evidence idenfying BBB dysfunction in AD or patients at risk (i.e. those with mild cognitive impairment) continue to escalate. This review highlights methodological issues facing investigators assessing BBB integrity in living patients while also discussing whether the BBB dysfunction is a cause, effect or epiphenomenon in AD. Rationale for future research pursuits aimed at describing the role of BBB function in AD pathogenesis is also presented.

AB - Successful prevention and treatment of late-onset Alzheimer's disease (AD) is a high priority for industrialized societies where the incidence is growing rapidly. Much of the underlying biology leading to AD is unknown, and the more knowledge we gain the more we appreciate the complexities involved. Popular etiologic hypotheses have largely ignored the blood-brain barrier (BBB) as an important factor contributing to the pathologic hallmarks of this most common form of dementia. Evidence idenfying BBB dysfunction in AD or patients at risk (i.e. those with mild cognitive impairment) continue to escalate. This review highlights methodological issues facing investigators assessing BBB integrity in living patients while also discussing whether the BBB dysfunction is a cause, effect or epiphenomenon in AD. Rationale for future research pursuits aimed at describing the role of BBB function in AD pathogenesis is also presented.

KW - Albumin

KW - Alzheimer's disease

KW - Amyloid

KW - Blood-brain barrier

KW - Cerebral amyloid angiopathy

KW - Cholesterol

KW - Computed tomography

KW - Homocysteine

KW - Imaging

KW - LRP-1

KW - MRI

KW - PET

KW - RAGE

UR - http://www.scopus.com/inward/record.url?scp=39349083735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39349083735&partnerID=8YFLogxK

U2 - 10.2217/1745509X.4.1.47

DO - 10.2217/1745509X.4.1.47

M3 - Article

AN - SCOPUS:39349083735

VL - 4

SP - 47

EP - 57

JO - Aging Health

JF - Aging Health

SN - 1745-509X

IS - 1

ER -